Viking Therapeutics, Inc. (VKTX) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Operating expenses:
Research and development	45.0	31.9	23.6	19.0	13.7	9.0	7.0	22.2
General and administrative	10.7	10.7	9.1	7.1	5.3	4.8	5.0	1.2
Total operating expenses	55.7	42.7	32.7	26.2	19.1	13.8	12.0	23.5
Loss from operations	-55.7	-42.7	-32.7	-26.2	-19.1	-13.8	-12.0	-23.5

Other income (expense):
Amortization of financing costs
Interest income, net	0.7	3.2	7.1	3.2	0.0	0.0	-0.1	-0.1
Total other income, net	0.7	3.2	6.9	4.1	-1.5	-2.7	-11.4	1.6
Net loss	-55.0	-39.5	-25.8	-22.1	-20.6	-14.7	-23.4	-21.9

Other comprehensive loss, net of tax:
Unrealized loss on securities	-0.5	-0.1
Foreign currency translation loss	0.0
Comprehensive loss	-55.5	-39.6	-25.3	-22.5	-20.6	-14.7	-23.4	-21.9

Basic net loss per common share	($0.71)	($0.54)	($0.36)	($0.38)	($0.79)	($0.90)	($3.68)	($5.23)

Weighted-average shares used to compute basic net loss per share	77.2	72.6	72.0	57.6	26.0	16.3	6.4	4.2
Diluted net loss per common share	($0.71)	($0.54)	($0.36)	($0.38)	($0.79)	($0.90)	($3.68)	($5.23)
Weighted-average shares used to compute diluted net loss per share	77.2	72.6	72.0	57.6	26.0